$295.39
1.16% today
Nasdaq, Jul 21, 06:17 pm CET
ISIN
US91307C1027
Symbol
UTHR

United Therapeutics Corporation Stock price

$292.01
+0.29 0.10% 1M
-66.92 18.64% 6M
-60.83 17.24% YTD
-36.66 11.15% 1Y
+57.90 24.73% 3Y
+176.67 153.17% 5Y
+114.50 64.50% 10Y
+265.75 1,011.78% 20Y
Nasdaq, Closing price Fri, Jul 18 2025
-5.32 1.79%
ISIN
US91307C1027
Symbol
UTHR
Sector
Industry

Key metrics

Basic
Market capitalization
$13.2b
Enterprise Value
$10.1b
Net debt
positive
Cash
$3.3b
Shares outstanding
45.1m
Valuation (TTM | estimate)
P/E
11.7 | 10.2
P/S
4.4 | 4.0
EV/Sales
3.4 | 3.0
EV/FCF
8.9
P/B
1.9
Financial Health
Equity Ratio
87.5%
Return on Equity
18.6%
ROCE
20.0%
ROIC
27.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$3.0b | $3.3b
EBITDA
$1.5b | $1.7b
EBIT
$1.4b | $1.5b
Net Income
$1.2b | $1.3b
Free Cash Flow
$1.1b
Growth (TTM | estimate)
Revenue
19.9% | 14.6%
EBITDA
12.9% | 11.0%
EBIT
11.7% | 2.4%
Net Income
15.2% | 7.8%
Free Cash Flow
50.0%
Margin (TTM | estimate)
Gross
89.0%
EBITDA
49.5% | 51.2%
EBIT
46.9%
Net
40.4% | 39.1%
Free Cash Flow
37.7%
More
EPS
$24.9
FCF per Share
$25.0
Short interest
4.7%
Employees
1k
Rev per Employee
$2.2m
Show more

Is United Therapeutics Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,010 stocks worldwide.

United Therapeutics Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a United Therapeutics Corporation forecast:

13x Buy
65%
7x Hold
35%

Analyst Opinions

20 Analysts have issued a United Therapeutics Corporation forecast:

Buy
65%
Hold
35%

Financial data from United Therapeutics Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,994 2,994
20% 20%
100%
- Direct Costs 329 329
18% 18%
11%
2,665 2,665
20% 20%
89%
- Selling and Administrative Expenses 664 664
25% 25%
22%
- Research and Development Expense 526 526
23% 23%
18%
1,481 1,481
13% 13%
49%
- Depreciation and Amortization 77 77
41% 41%
3%
EBIT (Operating Income) EBIT 1,404 1,404
12% 12%
47%
Net Profit 1,211 1,211
15% 15%
40%

In millions USD.

Don't miss a Thing! We will send you all news about United Therapeutics Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

United Therapeutics Corporation Stock News

Neutral
Business Wire
5 days ago
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public...
Neutral
Business Wire
27 days ago
EDEN PRAIRIE, Minn. & MURRAY, Utah--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, and Intermountain Health, one of the nation's top health systems and the largest nonprofit health system in the Intermountain West, today announced the world's first patient treated in a clinical study of a bioengineered external liver assist product called mirolive...
Neutral
Business Wire
28 days ago
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the conclusion of enrollment of the phase 3 ADVANCE OUTCOMES study evaluating the use of an extended-release formulation of ralinepag for the treatment of pulmonary arterial hypertension (PAH). The ADVANCE OUTCOMES study enrolled 728 partici...
More United Therapeutics Corporation News

Company Profile

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Head office United States
CEO Martine Rothblatt
Employees 1,305
Founded 1996
Website www.unither.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today